Indaptus Therapeutics (NASDAQ:INDP) Shares Up 1.5%

Shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) shot up 1.5% during mid-day trading on Wednesday . The stock traded as high as $2.09 and last traded at $2.08. 5,627 shares were traded during mid-day trading, a decline of 91% from the average session volume of 63,845 shares. The stock had previously closed at $2.05.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Indaptus Therapeutics in a report on Monday, April 15th.

Indaptus Therapeutics Trading Up 1.5 %

The company has a market capitalization of $17.76 million, a PE ratio of -1.13 and a beta of 1.28. The stock’s fifty day moving average is $2.26 and its two-hundred day moving average is $2.06.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings data on Wednesday, March 13th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.07. As a group, analysts anticipate that Indaptus Therapeutics, Inc. will post -1.83 EPS for the current fiscal year.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.